Accenture and Orexo to Launch INTIENT™ Platform

Accenture and Orexo to Launch INTIENT™ Platform

Healthcare Tech Outlook | Tuesday, November 24, 2020

Accenture assisted company Orexo to launch its first digital therapeutic, vorvida for the patients suffering from alcohol usage.

FREMONT, CA: Accenture has assisted the U.S. subsidiary of Swedish pharmaceutical company Orexo to launch its first digital therapeutic, vorvida. It can be used for patients in the United States who are dealing with problematic alcohol usage. vorvida is a web-based digital platform that utilizes the INTIENT Patient solution suite, which is driven by Google Cloud so that it can help to secure patient interactions and connectivity to an ecosystem of third-party health care services.

The important aspect of offering this population with the latest treatment choice was to develop a digital solution that could instantly connect patients with health care services and scale to support the portfolio of Orexo's future digital therapies, like the ones available for depression and opioid abuse.

"We are delighted to work with Accenture to make our digital therapies even more accessible to those who need them," said Dennis Urbaniak, executive vice president, Digital Therapeutics, Orexo. "We know that many of our patients are concerned with confidentiality and privacy, and the INTIENT™ Platform provides a safe, secure platform through which individuals struggling with mental or behavioral issues can confidently get the care they need – right at their fingertips."

The digital therapeutics are clinically confirmed patient treatments that offer access to novel care models and deliver health results by utilizing a collaboration of digital inputs, artificial intelligence algorithms, and interventions to impact patients' healthy behaviors. Orexo's digital therapeutics are developed so that it becomes easy to learn from interactions and personalize the delivery of content to fit the unique requirements of the individual. Apart from vorvida, Orexo even provides deprexis, which is used for the treatment of depression and anxiety, and modia for the treatment of opioid use disorder, it estimated to be available in the U.S. by the end of the year.

"Orexo is a great example of how INTIENT™ is supporting the future of the life science industry, driven by a focus on New Science, by providing a secure digital solution for patient data and connectivity to the market of digital health innovations and services," said Tony Romito, managing director, Global Patient Service, Accenture.

Weekly Brief